Special Issue

Recent Advances in Radiopharmaceutics

Message from the Guest Editor

Development of radiopharmaceuticals is important for diagnosis and/or radionuclide therapy in nuclear medicine with positron emission tomography (PET) and single photon emission computed tomography (SPECT). It also has translational potential from preclinical to clinical study in fields of oncology, neurodegenerative diseases, cardiovascular disease, etc. for personalized medicine. Integrative imaging and therapy in combination with other modalities, magnetic resonance imaging, ultrasonography, and near infrared imaging, etc., may move the personalized medicine further. In addition, advances of PET and SPECT scanners emphasize the usefulness of radiopharmaceuticals. This Special Issue will focus on synthesis and evaluation of new radiopharmaceuticals, other applications of radiopharmaceuticals for clinical studies, and the combination of a radionuclide with other modalities. Novel PET and SPECT machines are also targeted.

Guest Editor

Prof. Dr. Masato Kobayashi

Faculty of Health Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, 5-11-80 Kodatsuno, Kanazawa 920-0942, Japan

Deadline for manuscript submissions

closed (10 September 2022)

Pharmaceutics

About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:
indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:
JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:
manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).